Abu Dhabi expands footprint in pharmaceutical research, development

Advanced medicines and pharmaceuticals will be manufactured in Abu Dhabi, following an agreement between AstraZeneca and the A.I.-powered healthcare company, G42 Healthcare.

It's part of efforts to strengthen the emirate’s position as a hub for research and innovation in life sciences.

The agreement outlines collaboration in four key areas, including localisation of manufacturing, research and development, as well as sustainable production of innovative drugs.

It's the latest in a series of longstanding partnerships with key players in the pharmaceutical industry.

The agreement contributes to the ongoing efforts to establish a competitive knowledge economy by unlocking the potential of the UAE’s national capabilities.

It also factors in the Abu Dhabi’s Industrial Strategy in doubling the size of the manufacturing sector by 2031.

The partnership was confirmed through the signing of a five-year pact between G42 Healthcare and AstraZeneca.

All parties will collaborate closely to deliver cutting-edge science and activities supporting the provision of life changing medication to patients in the UAE and beyond.

Supported by @DoHSocial and its efforts to continuously enhance the emirate’s healthcare ecosystem, G42 Healthcare has partnered with AstraZeneca to manufacture advanced medicines in #AbuDhabi, reaffirming the emirate’s position as a hub for investment in life sciences. pic.twitter.com/F12TlUJsy7

— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 20, 2022

In recent years, Abu Dhabi's Department of Health (DoH) has established key collaborations with renowned healthcare organisations in an effort to expand knowledge and experience sharing.

Through an MoU signing earlier this year, Abu Dhabi has been home to AstraZeneca’s real-world evidence study on Evusheld, a pre-exposure COVID-19 treatment for immunocompromised patients.

Adding another layer to this partnership, DoH joined AstraZeneca’s A.Catalyst network to enhance digital healthcare in Abu Dhabi and improve patient experience and outcomes.